[浸润性黏液腺癌的分子机制和临床治疗进展]。

Minjun Shi, Bo Ye
{"title":"[浸润性黏液腺癌的分子机制和临床治疗进展]。","authors":"Minjun Shi, Bo Ye","doi":"10.3779/j.issn.1009-3419.2024.106.22","DOIUrl":null,"url":null,"abstract":"<p><p>Invasive mucinous adenocarcinoma (IMA) is a special type of lung adenocarcinoma that accounts for 2% to 10% of all lung adenocarcinoma. Surgical treatment is preferred for IMA, and traditional chemotherapy drugs and targeted therapy drugs have poor efficacy in this disease. IMA has unique prognostic, imaging and molecular features. The incidence of IMA is very low, so thoracic surgeons may lack of knowledge to the disease and misdiagnose it as benign diseases such as pneumonia and tuberculosis. This article reviews and discusses the imaging, clinicopathological features, treatment methods and prognosis of IMA.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"27 9","pages":"685-690"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534550/pdf/","citationCount":"0","resultStr":"{\"title\":\"[Advances on Molecular Mechanism and Clinical Treatment \\u2029in Invasive Mucinous Adenocarcinoma].\",\"authors\":\"Minjun Shi, Bo Ye\",\"doi\":\"10.3779/j.issn.1009-3419.2024.106.22\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Invasive mucinous adenocarcinoma (IMA) is a special type of lung adenocarcinoma that accounts for 2% to 10% of all lung adenocarcinoma. Surgical treatment is preferred for IMA, and traditional chemotherapy drugs and targeted therapy drugs have poor efficacy in this disease. IMA has unique prognostic, imaging and molecular features. The incidence of IMA is very low, so thoracic surgeons may lack of knowledge to the disease and misdiagnose it as benign diseases such as pneumonia and tuberculosis. This article reviews and discusses the imaging, clinicopathological features, treatment methods and prognosis of IMA.\\u2029.</p>\",\"PeriodicalId\":39317,\"journal\":{\"name\":\"中国肺癌杂志\",\"volume\":\"27 9\",\"pages\":\"685-690\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534550/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国肺癌杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3779/j.issn.1009-3419.2024.106.22\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国肺癌杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3779/j.issn.1009-3419.2024.106.22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

浸润性黏液腺癌(IMA)是一种特殊类型的肺腺癌,占所有肺腺癌的2%至10%。IMA首选手术治疗,传统化疗药物和靶向治疗药物对该病疗效不佳。IMA 具有独特的预后、影像和分子特征。IMA 发病率很低,因此胸外科医生可能对该病缺乏了解,将其误诊为肺炎和肺结核等良性疾病。本文回顾并讨论了 IMA 的影像学、临床病理学特征、治疗方法和预后。.
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[Advances on Molecular Mechanism and Clinical Treatment 
in Invasive Mucinous Adenocarcinoma].

Invasive mucinous adenocarcinoma (IMA) is a special type of lung adenocarcinoma that accounts for 2% to 10% of all lung adenocarcinoma. Surgical treatment is preferred for IMA, and traditional chemotherapy drugs and targeted therapy drugs have poor efficacy in this disease. IMA has unique prognostic, imaging and molecular features. The incidence of IMA is very low, so thoracic surgeons may lack of knowledge to the disease and misdiagnose it as benign diseases such as pneumonia and tuberculosis. This article reviews and discusses the imaging, clinicopathological features, treatment methods and prognosis of IMA.
.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
中国肺癌杂志
中国肺癌杂志 Medicine-Pulmonary and Respiratory Medicine
CiteScore
1.40
自引率
0.00%
发文量
5131
审稿时长
14 weeks
期刊介绍: Chinese Journal of Lung Cancer(CJLC, pISSN 1009-3419, eISSN 1999-6187), a monthly Open Access journal, is hosted by Chinese Anti-Cancer Association, Chinese Antituberculosis Association, Tianjin Medical University General Hospital. CJLC was indexed in DOAJ, EMBASE/SCOPUS, Chemical Abstract(CA), CSA-Biological Science, HINARI, EBSCO-CINAHL,CABI Abstract, Global Health, CNKI, etc. Editor-in-Chief: Professor Qinghua ZHOU.
期刊最新文献
[A Case Report of EGFR-TKIs Resistant Secondary MET Gene Amplified 
Lung Squamous Cell Carcinoma and Literature Review]. [Advances of Neoadjuvant Targeted Therapy in ALK-positive Non-small Cell Lung Cancer]. [Application of Nano-drug Delivery Technology in Overcoming Drug Resistance 
in Lung Cancer]. [Clinicopathological Analysis of 14 Cases of Primary Pulmonary Lymphoepithelial Carcinoma]. [Immunotherapy for Extensive-stage Small Cell Lung Cancer: 
Research Progress and Future Perspectives].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1